EDV2209 – a Paradigm shift in the treatment of stroke.

Despite tremendous research efforts and a large number of clinical trials focused on developing treatments for stroke, the field's current state remains dismal. There are, at present, no efficient treatments nor promising drug candidates for this lethal and disabling condition. A different perspective with a new approach is therefore desperately needed.

Edvince's drug discovery and development is born out of founder and Professor Lars Edvinsson's extensive, fundamental and pioneering research of cerebral circulation, receptor regulation, stroke and migraines.

Edvince is now ready to conduct the first clinical trial in 2022 with its innovative and disruptive lead drug EDV2209, an orphan drug for the treatment of brain ischemia associated with severe subarachnoid hemorrhage (SAH).

The drug helps to keep the blood vessels in the brain open, allowing brain cells to receive oxygen and nutrients to prevent brain damage.